OTC Monograph & NDA Evaluation

U.S. FDA OTC Drug Monograph vs NDA Regulatory Pathway Selection

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Analyzing FDA’s dual pathways for OTC registration, guiding manufacturers to verify monograph exemptions or if an NDA submission is required.

Key answer

The U.S. FDA registers OTC drugs via two paths: the OTC Monograph (GRASE) pathway, which permits direct NDC listing and marketing if formulation, strength, indications, and labeling match published monographs; or the New Drug Application (NDA/ANDA) pathway, required when utilizing new chemicals, new dosing paths, or claims exceeding monographs.

Benefits of the OTC Monograph System

Most finished OTC exports (sunscreens, anti-dandruff shampoo, pain patches) leverage the Monograph system, reducing time-to-market compared to NDA pathways.

  • No submission fee: Monograph listing has zero review fees, requiring only facility user fees
  • No pre-market approval: if active and warnings match the Monograph, NDC is active immediately upon submission
  • Clear specs: FDA sets exact concentration thresholds (e.g., salicylic acid 0.5%-2%)

FAQ

What if inactive ingredients exceed Monograph limits?+

Inactive ingredients (excipients) must comply with FDA’s Inactive Ingredient Database (IID) limits. If a preservative or surfactant exceeds historical exposure limits, the FDA classifies it as an unapproved drug, requiring NDA review or import alerts.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.